128 related articles for article (PubMed ID: 3059767)
1. Identification and characterization of a non-interferon antileishmanial macrophage activating factor (antileishmanial MAF).
Van Niel A; Zacks SE; David JR; Remold HG; Weiser WY
Adv Exp Med Biol; 1988; 239():231-7. PubMed ID: 3059767
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages.
Weiser WY; Van Niel A; Clark SC; David JR; Remold HG
J Exp Med; 1987 Nov; 166(5):1436-46. PubMed ID: 3119759
[TBL] [Abstract][Full Text] [Related]
3. Identification of a unique T cell-derived lymphokine that primes macrophages for tumor cytotoxicity.
Kern DE; Grabstein KH; Okuno K; Schreiber RD; Greenberg PD
J Immunol; 1989 Dec; 143(12):4308-16. PubMed ID: 2687379
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of a human T cell line-derived lymphokine with MAF-like activity distinct from interferon-gamma.
Lee JC; Rebar L; Young P; Ruscetti FW; Hanna N; Poste G
J Immunol; 1986 Feb; 136(4):1322-8. PubMed ID: 3003193
[TBL] [Abstract][Full Text] [Related]
5. T-cell hybridomas reveal two distinct mechanisms of antileishmanial defense.
Sypek JP; Wyler DJ
Infect Immun; 1990 May; 58(5):1146-52. PubMed ID: 2323812
[TBL] [Abstract][Full Text] [Related]
6. Partial purification and characterization of a human lymphokine which induces antileishmanial activity in mouse macrophages.
Buchmuller Y; Weiser WY; Remold HG
Cell Immunol; 1985 Jan; 90(1):242-50. PubMed ID: 3881189
[TBL] [Abstract][Full Text] [Related]
7. A lymphokine distinct from interferon-gamma that activates human monocytes to kill Leishmania donovani in vitro.
Hoover DL; Finbloom DS; Crawford RM; Nacy CA; Gilbreath M; Meltzer MS
J Immunol; 1986 Feb; 136(4):1329-33. PubMed ID: 3080522
[TBL] [Abstract][Full Text] [Related]
8. Constitutive production of novel macrophage-activating factor(s) by human T cell hybridomas.
Taniyama T; Taki S; Akiyama Y; Yoshizawa K; Hamuro J; Arai K; Wong GG
Clin Invest Med; 1990 Dec; 13(6):305-12. PubMed ID: 2127737
[TBL] [Abstract][Full Text] [Related]
9. Role of lymphokines in regulation of macrophage differentiation.
Onozaki K; Akagawa KS; Haga S; Miura K; Hashimoto T; Tokunaga T
Cell Immunol; 1983 Feb; 76(1):129-36. PubMed ID: 6339080
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte supernatant-induced human monocyte tumoricidal activity: dependence on the presence of gamma-interferon.
Sadlik JR; Hoyer M; Leyko MA; Horvat R; Parmely M; Whitacre C; Zwilling B; Rinehart JJ
Cancer Res; 1985 May; 45(5):1940-5. PubMed ID: 3921233
[TBL] [Abstract][Full Text] [Related]
11. T-cell hybridoma production of macrophage activation factor (MAF) I. Separation of MAF from interferon gamma.
Ratliff TL; Thomasson DL; McCool RE; Catalona WJ
J Reticuloendothel Soc; 1982 May; 31(5):393-7. PubMed ID: 6181257
[TBL] [Abstract][Full Text] [Related]
12. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.
Nathan CF; Murray HW; Wiebe ME; Rubin BY
J Exp Med; 1983 Sep; 158(3):670-89. PubMed ID: 6411853
[TBL] [Abstract][Full Text] [Related]
13. Activation of human monocyte cytotoxicity by natural and recombinant immune interferon.
Le J; Prensky W; Yip YK; Chang Z; Hoffman T; Stevenson HC; Balazs I; Sadlik JR; Vilcek J
J Immunol; 1983 Dec; 131(6):2821-6. PubMed ID: 6417232
[TBL] [Abstract][Full Text] [Related]
14. Identification of a T cell hybridoma that produces large quantities of macrophage-activating factor.
Schreiber RD; Altman A; Katz DH
J Exp Med; 1982 Sep; 156(3):677-89. PubMed ID: 7050288
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a human T-cell hybridoma that produces human macrophage activating factor for superoxide production and translation of messenger RNA of the factor in Xenopus laevis oocyte.
Miyamoto D; Nakamura N; Ishii Y; Kobayashi Y; Osawa T
Mol Immunol; 1987 Mar; 24(3):239-45. PubMed ID: 3039355
[TBL] [Abstract][Full Text] [Related]
16. Biological and biochemical characterization of macrophage activating factor (MAF) in murine lymphocytes: physiocochemical similarity of MAF to gamma interferon (IFN-gamma).
Fukazawa Y; Kagaya K; Miura H; Shinoda T; Natori K; Yamazaki S
Microbiol Immunol; 1984; 28(6):691-702. PubMed ID: 6434908
[TBL] [Abstract][Full Text] [Related]
17. Characterization of human macrophage activation factor (MAF) prepared from antigen-stimulated lymphocytes.
Cameron DJ
J Clin Lab Immunol; 1984 Jan; 13(1):47-50. PubMed ID: 6371237
[TBL] [Abstract][Full Text] [Related]
18. Human macrophage-activating factors for cytotoxicity. I. Establishment of a human T-cell hybridoma that produces macrophage-activating factors for cytotoxicity.
Higuchi M; Sugimoto M; Kobayashi Y; Osawa T
Microbiol Immunol; 1987; 31(5):469-79. PubMed ID: 3116371
[TBL] [Abstract][Full Text] [Related]
19. Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset.
Nakajima H; Izumi Y; Sugihara S; Satoh Y; Isumi S; Gotoh T; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1987; 25(3):201-8. PubMed ID: 3119213
[TBL] [Abstract][Full Text] [Related]
20. Macrophage activation for antileishmanial defense by an apparently novel mechanism.
Wyler DJ; Beller DI; Sypek JP
J Immunol; 1987 Feb; 138(4):1246-9. PubMed ID: 3100630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
